Calcitonin Gene-Related Peptide Inhibitor Use in 2018–2023: A Retrospective Cohort Study Across Six Canadian Provinces

CGRP inhibitor use increased from 2018 to 2023. After CGRP inhibitor initiation, most patients had concomitant use with a different prophylactic migraine medication class, and some stopped use; migraine-related acute medication and healthcare use were lower (versus before). Findings provide a real-world description of the evolving landscape of CGRP inhibitor use in Canada.